Diabetes Care After Transplant: Definitions, Risk Factors, and Clinical Management

Amisha Wallia, Vidhya Illuri, Mark E. Molitch*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Patients who undergo solid organ transplantation may have preexisting diabetes mellitus (DM), develop new-onset DM after transplantation (NODAT), or have postoperative hyperglycemia that resolves shortly after surgery. Although insulin is usually used to control hyperglycemia in the hospital, following discharge most of the usual diabetes oral and parenteral medications can be used in treatment. However, when there are comorbidities such as impaired kidney or hepatic function, or heart disease, special precautions may be necessary. In addition, drug-drug intreractions, such as drugs interacting with CYP3A4 enzyme pathway, require additional consideration because of possible interaction with immunosuppressive drug metabolism.

Original languageEnglish (US)
Pages (from-to)535-550
Number of pages16
JournalMedical Clinics of North America
Issue number3
StatePublished - May 1 2016


  • Diabetes
  • Immunosuppression
  • Insulin
  • Kidney
  • Liver
  • Transplant
  • Transplantation

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Diabetes Care After Transplant: Definitions, Risk Factors, and Clinical Management'. Together they form a unique fingerprint.

Cite this